In a Phase II trial a combination targeted therapy achieved a 51% overall response rate in patients with cholangiocarcinoma and BRAF V600E mutations. This is the first prospective study for this group of patients.
source https://www.sciencedaily.com/releases/2020/08/200817191745.htm
Recommended Blogs
Popular Posts
-
When you belong to the richest men community, you not only have luxury but have beautiful ladies too. Here we’ll be talking about exes and ...
-
We're sure the Croats are going to remember it for the rest of their lives - not only because Croatia got its first female president thi...
-
News, well let’s face it can be quite boring for some of us. I especially go nuts when the news channel comes on because I just cannot stand...
-
Plan your dream vacation to one of these superlative destinations. The world is full of diverse destinations that are waiting to be explor...
-
At least 26 people were shot dead by gunman and at least 24 others are being treated for injuries Devin Patrick Kelley, 26, a married father...
-
The North Korean mountain which has hosted a succession of nuclear tests appears to have suffered serious geological damage. Analysts now be...
-
When you apply for Aadhaar Card , it is essential to provide your email address and registered mobile number. In case you fail to do so, ...
-
The threat posed to bees by pesticides has been confirmed in a major new EU evaluation that could pave the way for a Europe-wide ban on th...
-
After Tokyo Commuter Train Leaves 20 Seconds Early, Company Apologizes A Japanese train company says it has spoken to a crew that left...
0 comments: